TSE:FRX Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free FRX Stock Alerts C$15.10 +0.29 (+1.96%) (As of 03/28/2024 ET) Add Compare Share Share Today's RangeC$15.10▼C$15.1050-Day RangeC$12.02▼C$15.2052-Week RangeC$9.27▼C$15.43Volume100 shsAverage Volume904 shsMarket CapitalizationC$408.30 millionP/E RatioN/ADividend Yield2.02%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Fennec Pharmaceuticals alerts: Email Address Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Fennec Pharmaceuticals Stock (TSE:FRX)Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Read More FRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FRX Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comCapital One Financial Weighs in on Fennec Pharmaceuticals Inc.'s FY2028 Earnings (TSE:FRX)March 25, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Fennec Pharmaceuticals Inc. (TSE:FRX) Decreased by WedbushMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 23, 2024 | seekingalpha.comFennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Fennec Pharmaceuticals Inc. (TSE:FRX) Cut by AnalystMarch 22, 2024 | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finanznachrichten.deFennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | americanbankingnews.comFY2024 EPS Estimates for Fennec Pharmaceuticals Inc. Reduced by Analyst (TSE:FRX)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 20, 2024 | americanbankingnews.comFennec Pharmaceuticals Inc. Expected to Post Q2 2024 Earnings of $0.12 Per Share (TSE:FRX)March 19, 2024 | ca.finance.yahoo.comStocks in play: Fennec Pharmaceuticals Inc.March 17, 2024 | markets.businessinsider.comFennec, Norgine Reach Licensing Deal To Commercialize Pedmarqsi In Europe, Australia, & New ZealandFebruary 29, 2024 | finance.yahoo.comFennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 ResultsFebruary 23, 2024 | finance.yahoo.comFENC Mar 2024 10.000 callFebruary 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Societal CDMO (SCTL)December 6, 2023 | finance.yahoo.comWith 31% stake, Fennec Pharmaceuticals Inc. (NASDAQ:FENC) seems to have captured hedge funds investors' interestDecember 1, 2023 | morningstar.comFennec Pharmaceuticals Inc FRXNovember 9, 2023 | seekingalpha.comFennec Pharmaceuticals Expands Possible TAM SignificantlyNovember 9, 2023 | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesNovember 7, 2023 | finance.yahoo.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | finance.yahoo.comQ3 2023 Fennec Pharmaceuticals Inc Earnings CallNovember 3, 2023 | benzinga.comPreview: Fennec Pharmaceuticals's EarningsNovember 1, 2023 | finance.yahoo.comInvestors in Fennec Pharmaceuticals (NASDAQ:FENC) have unfortunately lost 20% over the last yearOctober 30, 2023 | finance.yahoo.comFennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023October 5, 2023 | finance.yahoo.comAnalysts Expect Breakeven For Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Before LongSeptember 30, 2023 | theglobeandmail.comClosing Bell: Fennec Pharmaceuticals Inc up on Friday (FRX)August 23, 2023 | theglobeandmail.comFennec Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX (FRX)See More Headlines Receive FRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Next Earnings (Estimated)5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:FRX CUSIPN/A CIKN/A Webfennecpharma.com Phone+1-919-6364530FaxN/AEmployees36Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($1.01) Trailing P/E RatioN/A Forward P/E Ratio34.95 P/E GrowthN/ANet IncomeC$-20,220,000.00 Net Margins-154.92% Pretax MarginN/A Return on Equity-1,005.59% Return on Assets-43.20% Debt Debt-to-Equity Ratio881.09 Current Ratio4.84 Quick Ratio10.17 Sales & Book Value Annual SalesC$13.05 million Price / Sales31.29 Cash FlowC$1.30 per share Price / Cash Flow11.66 Book ValueC($0.40) per share Price / Book-37.75Miscellaneous Outstanding Shares27,040,000Free FloatN/AMarket CapC$408.30 million OptionableNot Optionable Beta0.35 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Rostislav Raykov (Age 48)CEO & Director Comp: $831.07kMr. Robert C. Andrade (Age 49)Chief Financial Officer Comp: $580.4kMr. Adrian J. Haigh (Age 65)Chief Operating Officer Comp: $54.13kMr. Mark GowlandControllerMr. Lei FangPresident of Pharstat IncKey CompetitorsProMetic Life SciencesTSE:PLIVIVO CannabisCVE:ABCNEmblemCVE:EMCBriaCell TherapeuticsCVE:BCTSernovaTSE:SVAView All CompetitorsInsidersChris Anigeron RallisSold 269 sharesTotal: C$2,219.25 ($8.25/share)Khalid IslamBought 20,492 shares on 11/16/2023Total: C$50,000.48 ($2.44/share)Rostislav Christov RaykovBought 74,793 shares on 11/3/2023Total: C$118,920.87 ($1.59/share)Chris Anigeron RallisSold 916 sharesTotal: C$7,639.44 ($8.34/share)View All Insider Transactions FRX Stock Analysis - Frequently Asked Questions How have FRX shares performed in 2024? Fennec Pharmaceuticals' stock was trading at C$15.16 at the beginning of 2024. Since then, FRX stock has decreased by 0.4% and is now trading at C$15.10. View the best growth stocks for 2024 here. When is Fennec Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FRX earnings forecast. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Encanto Potash (EPO), Acadian Timber (ADN), Agellan Commercial Real Estate Invtmt TR (ACR.UN), AutoCanada (ACQ), ATCO (ACO.X), Accord Financial (ACD), Aurora Cannabis (ACB), Air Canada (AC) and Barrick Gold (ABX). How do I buy shares of Fennec Pharmaceuticals? Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:FRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.